Nick Galakatos

Nick Galakatos, Senior Managing Director and Global Head of Life Sciences at Blackstone, dives deep into the evolving landscape of life sciences funding. He reveals that developing a new drug can exceed $2 billion, stressing how AI and innovation are reshaping this costly process. Galakatos discusses Blackstone's unique approach to investing in products rather than companies, focusing on promising therapies that could significantly impact patient care. He also explores the FDA's stable review timelines and highlights the current innovation-driven opportunities in an uncertain market.